The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene had been isolated as an antagonist to RAS signaling; however, the mechanism of its action is not clear. In this study, the effect of loss of RECK function was assessed in various ways and cell systems. Successive cell cultivation of mouse embryonic fibroblasts (MEFs) according to 3T3 protocol revealed that the germline knockout of RECK confers accelerated cell proliferation and early escape from cellular senescence associated with downregulation of p19
Introduction
The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene is a negative transcriptional target of various viral oncogenes including activated K-RAS Sasahara et al., 1999; Liu et al., 2003; Hsu et al., 2006) , and a negative post-transcriptional target of oncogenic microRNAs including miR-21 (Hu et al., 2008; Gabriely et al., 2008; Zhang et al., 2008; reviewed in Nicoloso et al., 2009; Loayza-Puch et al., 2010) . Furthermore, histone modification and DNA methylation have also been reported to be involved in the transcriptional regulation of RECK (Chang et al., 2004 (Chang et al., , 2007 . RECK expression is frequently correlated with a favorable prognosis in patients with various types of cancer (reviewed in Clark et al., 2006 Clark et al., , 2007 Noda and Takahashi, 2007) . However, the biological significance of these findings and mechanisms underlying them are still unclear. RECK has been proposed to be implicated in the extracellular signaling ), but it is not clear which signaling pathway (receptor) is actually influenced by RECK. Although our previous reports indicated that RECK exerts its functions through interaction with matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease 10 (ADAM10) Oh et al., 2001; Miki et al., 2007; Muraguchi et al., 2007) , it is still difficult to determine whether RECK is a bona fide membrane-anchored MMP/ ADAM inhibitor or whether MMP/ADAM inhibition is one of its multiple functions. We recently identified two RECK domains whose primary structures are homologous to that of a common substrate of several MMPs, and these domains were very slowly cleaved by the excessive amount of MMPs (Takegami and Takahashi, in preparation for publication). This may explain the ability of recombinant soluble RECK to competitively inhibit the proteolytic activity of recombinant soluble MMPs or membrane type 1 MMP (MT1-MMP), even though its inhibitory effect on these protease activities is weaker than tissue inhibitors of metalloproteinases (TIMPs) in in vitro assays Oh et al., 2001; Miki et al., 2007; Omura et al., 2009) .
RECK modulates the endocytic pathways of membrane-tethered metalloendopeptidases such as MT1-MMP and CD13/aminopeptidase N by changing their abundance in lipid raft through direct interaction . This appeared to shorten the life span of these membrane-tethered enzymes. RECK-deficient mouse embryos show premature differentiation in cortical neurons owing to downregulated Notch signaling caused by aberrant shedding of Delta-Serrate-Lag2 ligands in an ADAM10-dependent manner reviewed in D'Souza et al., 2008; Zolkiewska, 2008) . RECK appeared to bind directly to ADAM10 and allosterically inhibit its proteolytic activity . In contrast, the recombinant RECK protein has been shown to competitively inhibit MMPs Oh et al., 2001; Miki et al., 2007; Omura et al., 2009) . RECK and Delta-like family proteins (D'Souza et al., 2008; Zolkiewska, 2008) share structurally similar epidermal growth factor (EGF)-like repeats, which may serve as recognition signals for ADAM10. Although identification of the domains responsible for such protein-protein interaction is currently hampered by the extremely cysteine-rich primary structure of RECK , these findings suggest that RECK may function as more than a protease inhibitor.
To further address the basic functions of RECK in cells, in this study, we at first compared the short-and long-term effects of germline knockout with those of short hairpin RNA (shRNA)-mediated knockdown of RECK in early-passage mouse embryonic fibroblasts (MEFs). By shedding light on the differential effects of RECK deficiency dependent on the timing of downregulation, we attempted to identify cell signaling pathways modulated by RECK. Previous studies have linked RECK deficiency to deregulation of extracellular gelatinase activities and focal adhesion stability (Oh et al., 2001; Morioka et al., 2009) ; however, these studies employed RECK-deficient MEFs that have been cultivated for a long time (more than 35 passages). In this study, we propose that the primary effect of RECK deficiency appears in the control of cell cycle and cellular senescence. We identified EGF receptor (EGFR)/RAS pathway as one of the signaling pathways that are controlled by RECK.
Results
Differential effects of germline knockout and shRNAmediated knockdown of RECK on cell proliferation Consistent with a previous report (Hatta et al., 2009) , RECK expression was induced in MEFs by serum starvation and downregulated after release from serum restriction (Supplementary Figure S1a) . Moreover, contact-inhibition-dependent cell cycle arrest in the presence of serum was correlated with the increased RECK expression (Supplementary Figure S1b) . These findings implicated involvement of RECK in cell cycle control. In low passage number cell cultures, Reck À/À MEFs did not show remarkable differences in growth properties and gelatinase activities when compared with wild-type or Reck þ /À littermates (data not shown). However, successive cell cultivation of primary embryonic fibroblasts prepared from live embryonic day (E)10.0 embryos according to 3T3 protocol (Todaro and Green, 1963) revealed that after around 10 passages, Reck À/À MEFs displayed a higher proliferation rate, immortal cell growth and smaller cell size in comparison with wild-type littermates ( Figure 1a and data not shown); these findings suggest that germline knockout of RECK confers accelerated cell proliferation and early escape from cellular senescence. These phenotypes were correlated with downregulation of p19
Arf , Trp53 and p21
Cdkn1a
( Figure 1b) , and suppressed by the forced expression of p21 Cdkn1a ( Figure 1c ). We then attempted to determine the function of RECK in cells by directly depleting RECK in wild-type MEFs. Opposing to the results of the long-term analysis of germline knockout MEFs, lentivirus-mediated transduction with RECK-targeted shRNAs resulted in marked downregulation of cell proliferation (Figure 1d ). Furthermore, RECK depletion in such an acute manner upregulated p19 Arf , Trp53, p21
Cdkn1a and p16 Ink4a expression, with reciprocal downregulation of Mdm2 within 48 h after shRNA transduction (Figure 1e ). In the same experiment, we observed slight increase in Bax expression; however, we did not detect significant level of apoptosis in RECK-depleted MEFs by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (data not shown). These findings suggest that RECK controls cell proliferation by influencing the ARF/Tp53/ p21 Cdkn1a pathway. We eliminated the possibility of off-target effects by employing multiple sets of shRNA and appropriate controls. Moreover, whole cell lysates from live E9.5 Reck À/À embryos revealed marked induction of p21
( Figure 1f ) and reciprocal downregulation of bromodeoxyuridine (BrdU) uptake (Figure 1g ), both of which account for the smaller body size of RECK nullizygous embryos (Oh et al., 2001) Figure S2) . These findings suggest that Cdkn1a does not mediate the lethality caused by RECK deficiency and that the effect of deletion of these two genes is not synthetic, that is, their genetic relationship is linear.
Furthermore, 10 days after RECK depletion, we observed the evidence of cellular senescence in MEFs, as assessed by increased senescence-associated b-galactosidase activity, decreased BrdU uptake, increased p16 Ink4a expression and nuclear accumulation of trimethylated histone H3K9 (H3K9me3) (Figure 1h) . We eliminated the possibility that RECK depletion induced apoptosis in MEFs even at 10 days after shRNA transduction by performing terminal deoxynucleotidyl transferasemediated dUTP nick end labeling staining (data not shown). In addition, we observed neither induction nor accumulation of gH2AX in these senesced cells (Figure 1i ), eliminating the possibility that DNA damage response underlies the mechanism of RECK depletion-induced cellular senescence. Additionally, we observed that RECK depletion in an adipogenic fibroblast cell line, PA6, caused an arrest of cell growth without promoting adipogenic differentiation, as assessed by Oil Red O staining, and the induction of PPARg and C/EBPa (Supplementary Figures S3a and  b) , eliminating the possibility that RECK depletion may cause premature differentiation in cultured fibroblast cells. In addition, we noticed that in contrast to MEFs under serum restriction, RECK is downregulated in PA6 cells under differentiation-inducing condition (Supplementary Figure S3b) .
RECK depletion-induced cellular senescence depends on Arf, Trp53 and Cdkn1a but not on Ink4a To study the mechanism by which RECK depletion induces growth suppression and cellular senescence, we infected MEFs on various genetic backgrounds with lentivirus expressing RECK shRNAs. Arf
and Cdkn1a
À/À but not Ink4a À/À MEFs were insensitive to RECK shRNA-induced growth suppression ( Figure 2a ) and cellular senescence ( Figure 2b ). In Cdkn1a À/À MEFs, we observed that RECK depletion did not induce p16
Ink4a (Figure 2c ), suggesting that p16
Ink4a induction by RECK depletion depends on Cdkn1a loci. These findings suggest that RECK depletion-induced cellular senescence depends on Arf, Trp53 and Cdkn1a.
RECK depletion induces transient upregulation of AKT and ERK activities through the elevation of EGFR activity
To further clarify the mechanism by which RECK depletion induces growth suppression and cellular 
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S Kitajima et al senescence, we studied the activity of various intracellular signaling molecules. As we discovered RECK originally as a gene that antagonized RAS transformation in a cell phenotype-based cDNA screening (Takahashi et al., 1998), we particularly focused on RAS signaling. We identified increased phosphorylation of protein kinase B (AKT) and extracellular signalregulated kinase (ERK), and upregulated expression of cyclin D1; all these were induced within 48 h after shRNA-mediated RECK depletion in MEFs (Figure 3a) . To investigate the mechanism by which RECK functionally interacts with AKT and ERK, we tested numbers of inhibitors to various cellular signaling. We first conceived that RECK may modulate activity of receptors, as we observed in our previous studies Miki et al., 2010) . The increased phosphorylation of AKT and ERK induced by RECK depletion was sensitive to the receptor tyrosine kinase inhibitor genistein (4 0 ,5,7-trihydroxyisoflavone) (Supplementary Figure S4a) . As genistein inhibits broad range of receptor tyrosine kinases and others, we then examined more specific inhibitors. We found that gefitinib (N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-3-morpholin-4-ylpropoxy)quinazolin-4-amine), a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure 3a) . Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion, with insignificant change in its protein amount (Figure 3b ). The increased EGFR activity Figure S4b) and gefitinib ( Figure 3b ). These findings suggest that RECK depletion in an acute manner induces upregulation of AKT and ERK activities through the elevation of EGFR activity.
Mechanism of cellular senescence induced by shRNAmediated RECK depletion The induction of p19
Arf , Trp53 and p21 Cdkn1a by RECK depletion was sensitive to both genistein (Supplementary Figure S5a) and gefitinib (Figure 4a ), indicating that RECK depletion upregulated these molecules through EGFR signaling modulation. Moreover, we observed that Sprouty 2 upregulation was associated with EGFR activation and attenuated by treatment with genistein (Supplementary Figure S5b) or gefitinib (Figure 4b ). Sprouty 2 is upregulated by RAS signaling and thereafter antagonizes RAS activation through negative feedback mechanism (Courtois-Cox et al., 2006) at multiple points along the RAS regulatory pathway (Gross et al., 2001; reviewed in Kim and Bar-Sagi, 2004) . We monitored AKT and ERK activities in MEFs, 10 days after shRNA transduction; as expected, these activities were strongly downregulated (Figure 4c ). We further observed downregulated RAS activity in RECK-depleted cells (Figure 4d ), confirming suppression of RAS signaling. We examined whether simultaneous depletion of Sprouty 2 is sufficient to block the effects of RECK depletion on RAS signaling; however, the result was negative (data not shown). We speculated that as the negative feedback mechanism to RAS signaling involves more than 10 modulators of RAS signaling, that is, several RAS GTPase-activating proteins (RASGAPs), RASGEFs (RAS guanine-nucleotide exchange factors), Sprouty (suppressor of RAS) and Spred (Sprouty-related protein) family members and dual specificity phosphatases, simultaneous depletion of solely Sprouty 2 was insufficient to antagonize RECK depletion in suppressing RAS signaling.
Furthermore, both genistein (Supplementary Figure S5c ) and gefitinib (Figure 4e ) treatment partially, but significantly, abrogated the negative impact of shRNA-mediated , and the negative feedbacks to the RAS pathway including Sprouty 2 induction, subsequently leading to cellular senescence.
Overexpression of RECK attenuates RAS signaling in colon cancer cells
The abovementioned studies assessed the effects of loss of RECK function. We then assessed the effect of gain of RECK function on EGFR signaling. We first attempted to reconstitute RECK in Reck À/À MEFs and measure RAS signaling. We infected Reck À/À MEFs cultivated for B10 passages with retrovirus vector carrying RECK cDNA , selected with blasticidin and confirmed physiological level expression of RECK. However, we could not detect downregulation of RAS signaling in RECK-reconstituted Reck À/À MEFs (data not shown). We speculated that, in contrast to RECK depletion, which induces irreversible withdrawal from cell cycle, the effect of gain of RECK function on RAS signaling in MEFs is reversible and adjustable. We also thought that the downregulation of RAS signaling may generate disadvantage in clonal expansion during drug selection, thus it is difficult to demonstrate. Nonetheless, we thought that the transient overexpression of RECK may enable us to observe its negative impact on RAS signaling. We screened number of nontransformed and cancer-derived cell lines, with relatively high transfection competency to find out the one that is sensitive to RECK. We finally found that transient overexpression of human RECK in SW480 colon cancer cells was sufficient to downregulate AKT and ERK activities and cyclinD1 expression, and upregulate p21
Cdkn1a expression (Figure 5a ). In addition, RECK overexpression significantly suppressed EGFR activity (Figure 5b) . Altogether, the data obtained in this study indicate that RECK antagonizes RAS signaling through modulation of EGFR activation.
Treatment of MEFs by EGF and fibroblast growth factor strongly attenuated RECK expression (Supplementary Figure S6a ), consistent with our previous finding that oncogenic RAS attenuates RECK transcription Figure S6b) .
Mechanism of the RECK-EGFR genetic interaction
Finally, we addressed the mechanistic aspects of the RECK-EGFR genetic interaction. The exogenous introduction of wild-type RECK expression vector that is insensitive to our RECK shRNAs antagonized the effect of endogenous RECK depletion on cell growth (Figures 6a and b) . This again eliminated the possibility that the effects of RECK shRNAs on cell proliferation were the product of off-target effects. Interestingly, in the same setting, secreted form of RECK (RECKDC: one mutant lacking the membrane anchor) was unable to antagonize RECK shRNAs, indicating that membrane anchoring is required for RECK modulation of cell growth mediated by RAS signaling (Figures 6a  and b) . We have thus far been unable to detect a direct interaction between RECK and EGFR (data not shown).
Next, we hypothesized that increased metalloendopeptidase activities induced by RECK loss may affect cell growth and RAS signaling in MEFs. However, a broad spectrum (nonspecific) metalloendopeptidase inhibitor, GM6001, did not show antagonism to RAS signaling activation and growth arrest induced by RECK depletion (Figures 7a and b) . Then, we assessed specifically the MMP-2 and MT1-MMP dependency of RECK function in RAS signaling modulation, as it had been previously addressed in the context of embryonic development (Oh et al., 2001) , endocytosis and vascular development (Miki et al., 2010) . We first examined whether germline loss of MMP-2 or MT1-MMP antagonizes RECK depletion-induced growth suppression. Both MMP-2 À/À MEFs and MT1-MMP À/À MEFs exhibited partial but significant resistance to RECK depletion-induced growth suppression (Figure 7c ). More importantly, suppression of RAS signaling by RECK depletion was significantly lesser in those MEFs than in wild type (Figure 7d ). These findings suggest that MT1-MMP/MMP-2 system may mediate RECK to modulate EGFR signaling.
We finally addressed whether in other lineage of cells, RECK depletion-induced cellular senescence associates with RAS signaling downregulation in an MMP-2-dependent manner. Human umbilical endothelial cells (HUVECs) express MMP-2 (Jodele et al., 2006) . Our recent study has demonstrated that small interfering RNA-mediated RECK depletion in HUVECs induced proliferation defects and abnormal vascular development, in part, in an MMP-2-dependent manner (Miki et al., 2010) . In consistent with our current study using MEFs, small interfering RNAs targeting RECK induced upregulation of Sprouty 2 and reciprocal downregulation of ERK activity in HUVECs at 3 days after transduction; these were significantly antagonized by simultaneous introduction of MMP-2 small interfering RNAs (Supplementary Figure S7a) . In consonance, the growth suppression in HUVECs induced by RECK depletion was partially antagonized by simultaneous MMP-2 depletion (Supplementary Figure S7b) . These findings suggest a specific role of MMP-2 in the RECK-EGFR genetic interaction in multiple lineages of cells. 
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Discussion
In this study, the functions of RECK in cultured cells (MEFs, colon cancer cells and vascular endothelial cells) and embryos were assessed by a variety of 'loss of function' and 'gain of function' investigations. We concluded that RECK antagonizes RAS signaling by attenuating EGFR activation in multiple cell lineages. The precise mechanism of the RECK-EGFR genetic interaction and its dependency on MMP-2 and MT1-MMP is currently under intensive investigation. MMP-2 or MT1-MMP may indirectly influence on the ectodomain shedding of membrane-tethered growth factors binding to EGFR family members, which is thought to be mediated by ADAM members. However, so far, we did not observe change in the degree of ectodomain shedding of EGFR family ligands (TGFa, EGF, HB-EGF, betacellulin, amphiregulin and epiregulin) by modulating RECK expression (data not shown), and we so far did not detect direct binding of RECK and EGFR. Despite the marked induction of p21 Cdkn1a observed in whole embryos, MEFs separated from E10.0 Reck À/À embryos expressed p21
Cdkn1a at a level comparable with wild-type cells, suggesting that RECK deficiency causes a certain stress to the whole body, leading to p21 Cdkn1a induction or that p21
Cdkn1a level had been quickly adjusted to normal level under in vitro culture conditions during three passages. Acquirement of accelerated and immortal cell proliferation by Reck À/À MEFs during successive cell cultivation was closely correlated with attenuated p19
Arf , Trp53 and p21 Cdkn1a expression. In contrast, RECK depletion-induced cellular senescence required the presence of these loci. These seemingly mutually-contradicting findings helped us to conceive that the cellular signaling modulated by RECK could be bivalent in the control of cell proliferation. We then noticed that the notion of 'oncogene-induced senescence' (Collado and Serrano, 2010) and its revised version notion 'negative feedback to RAS signaling' (Courtois-Cox et al., 2008) may explain our findings.
Cellular senescence induced by oncogenic RAS has been proposed to be mediated by DNA hyper-replication and following DNA damage response (Bartkova et al., 2006; Di Micco et al., 2006) ; this may explain RECK depletion-induced cellular senescence. However, we eliminated this possibility by investigating several markers of DNA damage response including gH2AX (Figure 1i ) and phosphorylated Trp53 S15 (data not shown) in RECK-depleted MEFs. In addition, the positive sensitivity of Ink4a À/À MEFs to RECK depletion-induced cellular senescence may imply that the nature of RAS activation induced by RECK depletion differs from that of oncogenically mutated RAS. We further speculate that DNA damage may be a prerequisite for p16 
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The relationship between RECK and Sprouty 2 is highly similar to that initially noted between the neurofibromatosis type 1 (NF1) tumor suppressor gene and Sprouty 2 (Courtois- Cox et al., 2006) . NF1 is a member of the RASGAPs that suppresses RAS activation by promoting hydrolysis of GTP (reviewed in Cichowski and Jacks, 2001) . Activation of RAS signaling induced by NF1 inactivation provokes a series of negative feedback loops to RAS pathways by inducing the transactivation of many of antagonists to RAS signaling pathway, including the Sprouty and Spred family members, and many of RASGAPs and dual specificity phosphatases, in an AKT/FOXO-and retinoblastoma (Rb)/Trp53-dependent manner (CourtoisCox et al., 2006 ). Cichowski's research group thereby revised the 'oncogene-induced cellular senescence model' (Serrano et al., 1997) by proposing this negative feedback mechanism (Bardeesy and Sharpless, 2006) . We observed this mechanism in cells that acutely lost RECK function, highlighting the tumor suppressor trait of RECK gene more clearly than ever. We also speculate that, in contrast to the shRNA-mediated RECK depletion, the germline RECK knockout allowed cells to take enough time to override growth-suppressing signals involving negative feedback pathway before cellular senescence program was engaged. We are currently examining whether early escape from cellular senescence by Reck À/À MEFs depends on EGFR function. The strong clinical relevance of the tumor suppressor trait of RECK gene had been previously provided by a couple of studies that reported strong correlations between RECK expression and favorable prognosis for patients with non-small-cell lung cancer (Takenaka et al., 2004 (Takenaka et al., , 2005 whose malignant behaviors critically depend on EGFR signaling (reviewed in Andratschke et al., 2004; Ja¨nne, 2005) . In addition to non-small-cell lung cancer, RECK significantly predicts favorable prognosis in many types of cancer, including colorectal cancer (Rabien et al., 2007; Takemoto et al., 2007; Long et al., 2008; Rahmah et al., 2009; references in Clark et al., 2007 ; references in Noda and Takahashi, 2007) . Our current study demonstrated that RECK attenuates AKT and ERK in the SW480 colon cancer cell line, overriding the activating mutation in K-RAS harbored by this cell line (Anker et al., 1994) . We originally identified RECK as a gene product whose overexpression dominantly antagonizes oncogenic K-RAS-induced transformation . Altogether, our current study suggests that RECK antagonizes both physiological and oncogenic RAS signaling.
RECK transcription is suppressed by oncogenic RAS . As expected, the treatment of cells with EGF and fibroblast growth factor (FGF) strongly suppressed RECK expression in cell culture (Supplementary Figure S6a) . In this study, mutual suppression between RECK and RAS signaling was demonstrated (Supplementary Figure S6b) . In addition, many of retroviral oncogenes , oncogenic DNA virus products (Liu et al., 2003) and the so-called 'oncomir' (oncogenic microRNA) miR-21 (Gabriely et al., 2008; Hu et al., 2008; Zhang et al., 2008; reviewed in Nicoloso et al., 2009; Loayza-Puch et al., 2010) were demonstrated to negatively regulate RECK transcription. These findings indicate that these oncogenic signals may commonly impact on RAS signaling from the extracellular space through transcriptional regulation of RECK.
It was demonstrated that MMP-9 is transcriptionally regulated by RECK by transcription factors Fra-1 and c-Jun through 12-O-tetradecanoylphorbol-13-acetateresponsive-1 site in the MMP-9 promoter (Takagi et al., 2009) . Fra-1 and c-Jun are highly established downstream targets of EGFR signaling, and MMP-9 is indeed upregulated by EGF (Lyons et al., 1993) . There is a possibility that RECK directs MMP-9 transcription by modulating EGFR signaling. In addition, we recently determined that RECK is a direct substrate of several MMP activities (Takegami et al., in preparation for publication). It is possible that MMP activities enhance RAS signaling even by impairing RECK functions. We further speculate that RECK may function as a converter of extracellular protease activities to RAS signaling.
Finally, this study demonstrated that similar to loss of phosphatase and tensin homolog deleted from chromosome 10 (PTEN), NF1 or Von Hippel-Lindau disease (VHL) tumor suppressor genes (Chen et al., 2005; Courtois-Cox et al., 2006; Young et al., 2008) or activating mutation in several RAS isoforms or B-Raf (Braig et al., 2005; Michaloglou et al., 2005) , the effect of loss of RECK function on cell proliferation is counteracted by the cellular senescence program. Furthermore, we have recently reported that carcinogenesis induced by loss of the Rb tumor suppressor gene is antagonized by DNA damage response and cellular senescence induced by E2F-depednent activation of N-RAS . Therefore, we speculate that signals antagonistic to loss of many tumor suppressors may commonly converge on RAS signaling.
Materials and methods
Mice Reck
þ /À mice (Oh et al., 2001) were backcrossed to C57BL/6 mice for six generations, and intercrossed for timed pregnancy. Arf-knockout mice were gifted from T Kamijo (Kamijo et al., 1997) . Trp53-knockout mice (Tsukada et al., 1993) were obtained from RIKEN BRC (Tsukuba, Japan; acc. no. CDB0001K). Cdkn1a-knockout mice were gifted from P Leder (Deng et al., 1995) . Ink4a-knockout mice were from N Sharpless (Sharpless et al., 2001) . MMP2-knockout mice were from S Itohara (Itoh et al., 1997) and MT1-MMP-knockout mice were from Y Okada and M Seiki (Oh et al., 2004) . Animals were handled in accordance with the guidelines of the Kyoto University and the Kanazawa University.
Generation of MEFs
Primary MEFs were prepared as described previously ) from individual embryos of various genotypes, and maintained in a-modified Eagle's medium supplemented with 10% fetal bovine serum. Primary MEFs were used for each experiment before 10 passages.
3T3 protocol
A total of 2 Â 10 5 cells were plated in 60 mm diameter dishes. After 3 days, the total number of cells in each dish was counted using a particle counter (Coulter Counter Z1, Beckman Coulter, Brea, CA, USA), and 2 Â 10 5 cells were replated into the 60 mm diameter dishes. This procedure was repeated every 3 days for 20-30 passages.
Retrovirus and plasmids
Retroviruses were recovered from Ecopack293-2 (Clontech, Mountain View, CA, USA), transfected with pLXSB, pLXSBhuman RECK (hRECK) , pLXSBhRECKDC , pBabe-puro and pBabe-puro-p21. MEFs were plated 20 h before infection, and infected with virus in the presence of 8 mg/ml polybrene. The estimated multiplicity of infection was 2-3. At 24 h after infection, infected cells were selected in the presence of 8 mg/ml blasticidin or 2 mg/ml puromycin.
RNA interference MISSION TRC shRNA target sets for mouse RECK (sh-RECK no. 1: TRCN80129 and sh-RECK no. 2: TRCN80131), and those targeting luciferase (sh-luciferase: SHC007) and negative control (sh-negative control: SHC002) were purchased from Sigma-Aldrich (St Louis, MO, USA). Generation and infection of lentivirus were performed according to the manufacturer's instruction.
Proliferation assay
Cells were plated on 96-well-type plates (1 Â 10 3 cells per well). After shRNA-lentivirus infection, the cell numbers were quantified by colorimetric assay using cell count reagent SF (07553-15, Nacalai Tesque, Kyoto, Japan) according to the manufacturer's instructions.
Immunoblotting and immunofluorescence
Immunoblotting and immunofluorescence were performed in buffer or in acid-extraction buffer , as described previously using the following antibodies: p19
Arf (no. 07-543, Upstate, Temecula, CA, USA), Trp53 (1C12, Cell Signaling Technology, Danvers, MA, USA), p21 CDKN1A (no. 556430, BD Bioscience, San Jose, CA, USA), a-tubulin (Ab-1, Calbiochem, Gibbstown, NJ, USA), RECK , Mdm2 (4B11, Calbiochem), Bax (sc-493, Santa Cruz Biotechnology, Santa Cruz, CA, USA), p16
